Cloud DX Receives Partnership Funding for Clinical Research of Next Generation Wrist-Worn Vital-Sign Monitoring Device

The New Brunswick Health Research Foundation (NBHRF) partners with Cloud DX to fund Calibration and Validation research of its patented Pulsewave 2.0, a Non-Invasive Vital Sign Monitoring Device

News in Summary

• NBHRF is providing $131,902 to the New Brunswick research team for ongoing research of the clinical evaluation of the wrist-worn vital sign monitoring device, Pulsewave 2.0
• Cloud DX commits to R&D investment for clinical calibration and subsequent validation of a wrist-worn non-invasive health monitoring device to be conducted at the Horizon Health Network, Saint John Regional Hospital (SJRH)
• The NBHRF supports, facilitates, and promotes innovative health research in New Brunswick, Canada
• Research findings and data will be used for Health Canada licensing and FDA clearance of Cloud DX's next-generation Pulsewave 2.0, on its path to market as the only wrist cuff to accurately measure pulse rate, blood pressure, and respiratory rate in both home and clinical settings

KITCHENER, ON / ACCESSWIRE / January 13, 2022 / Cloud DX (TSXV:CDX)(OTCQB:CDXFF), Cloud DX announces new partner funding from the New Brunswick Health Research Foundation (NBHRF). This funding will support ongoing clinical calibration and subsequent validation trials with the Cloud DX Pulsewave 2.0 wrist-worn vital sign monitoring device.

The NBHRF Strategic Initiative Grant will be matched two to one by Cloud DX over three years to support the ongoing research and development led by Dr. Brunt and Dr. Teskey and their teams at Cardiovascular Research New Brunswick (CVR NB), Dalhousie Medicine New Brunswick (DMNB), University of New Brunswick (UNB) and the IMPART investigator team. The research will be conducted with the Department of Cardiology at the New Brunswick Heart Center at the Saint John Regional Hospital (SJRH), part of the Horizon Health Network.

Lead researcher & Translational Scientist, Dr. Keith Brunt states: "We are pleased to provide ongoing best-in-class R&D support to the development of medical technology innovations. We are committed to ensuring informed-decision making clinically is built upon strong evidence, validated intellectual property that is peer-reviewed and aligned with regulatory expectations for medical devices. Our prior clinical research with an earlier version of the device, was published in the Journal of Medical Internet Research, and key to the initial development of proprietary algorithms for the Pulsewave 2.0 device."